Flouroquinolone activity in clinical isolates of Streptococcus pneumoniae with different susceptibility to penicilline: An epidemiological study in five cities of Mexico;Actividad de las fluoroquinolonas en aislamientos clínicos de Streptococcus pneumoniae con diferente susceptibilidad a la penicilina: Estudio epidemiológico en cinco ciudades de la República Mexicana

Gaceta Medica de Mexico

Volumn 141, Issue 4, 2005, Pages 253-258

  Calva Mercado, Juan José ^a   Castillo, Gonzalo ^b   López Vidal, Yolanda ^b  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Antibiotic resistance; Fluoroquinolones; Mexico; Pneumococcus

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIUM ISOLATE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACTIVITY; EPIDEMIOLOGICAL DATA; HEALTH SURVEY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MEXICO; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTEREMIA; CIPROFLOXACIN; DATA INTERPRETATION, STATISTICAL; DRUG RESISTANCE; FLUOROQUINOLONES; HUMANS; MEXICO; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; OFLOXACIN; PENICILLIN RESISTANCE; PENICILLINS; QUINOLINES; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 24344443340     PISSN: 00163813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Appelbaum PC. Resistence among Streptococcus pneumoniae: Implications for drug selection. Clin Infect Dis 2002;34:1613-1620.
2. Hoban DJ, Doem GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide Prevalence of Antimicrobial Resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32 (Suppl 2):S81-S93.
3. Jacobs MR, Appelbaum PC. LASER Study Group. Susceptibility of 1 100 Streptococcus pneumoniae strains isolated in 1997 from seven Latin American and Caribbean countries, Inte J Antimicr Age 2000;16:17-A
4. Quiñones-Falconi F, Calva JJ, Lopez-Vidal Y, Galicia-Velazco M, Jiménez-Martínez ME, Larios-Mondragón L. Reduced susceptibility to penicillin of Streptococcus pneumoniae as a marker of multidrug resistance in Mexico. Diag Microbiol Infect Dis (enviado)
5. Jacobs MR. Drug-Resistant Streptococcus pneumoniae: Rational Antibiotic Choices. Am J Med 1999;1 06(5A):19S-25S
6. Scheld WM. Maintaining fluoroquinolone class efficacy: Review of influencing factors. Emer Infect Dise 2003;9:1-9.
7. Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis 2002;2(7):404-415.
8. Ho PL, Que TL, Tsang NCD, T-K NG, how K-H, Seto W-H. Emergence of fluoroquinolone resistance ainong multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999;43(5):1310-1313.
9. Ho PL, Yung RWH, Tsang DNC, Que TL, Ho M, Seto WH, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of Hong Kong multicentre study in 2000. J Antimicrob Chem 2001;48:659-665.
10. Davidson R, Cavalcanti R, Brunton JL, Bast Dj, de Azavedo JCS, Kibsey P, et al. Resistance to levofloxacin and faure Of treatment of pneuniococcal pneumonia. N Engl J Med 2002;346:747-750.
11. Ross JJ, Worthington MG, Gorbach SL. Resistance to levoiloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;347(1):65-66.
12. Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ. Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2000;31:347-382.
13. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of Community-acquired Pneumonia in the Era of Pneumococcal Resistance. Arch Intern Med 2000;160:1399-1408.
14. American Thoracic Society Official Statement. Guidelines for the Management of Adults with Community-acquired Pneumonia. Diagnosis, Assessment of Severity, Antimicrobial Therapy and Prevention. Am J Respir Crit Care Med 2001;163:1730-1754.
15. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; Ninth Informational Supplement [M100-S12]. Wayne Pensylvania: National Committee for Clinical Laboratory Standards, 2002 vol 21
16. Brueggemann AB, Coffiman SL, Rhomberg P, Huynh H, Almer L, Nilius A, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 2002;46(3):680-688.
17. Chen DK, McGeer A, de Azabedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-239
18. Pérez-Trallero E, Fernández-Mazarrasa C, García-Rey C, Bouza E, Aguilar L, García-de-Lomas J, et al. Antimicrobial susceptibilities of 1684 Streptococcus pneumoniae and 2039 Streptococcus pyogenes isolates and their ecological relationship: results of a one-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2002;4:3340.
19. White RL, Enzweiler KA, Friedrich LV, Wagner D, Hoban D, Bosso JA, et al. Comparative activity of gatifioxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000. Diag Microbiol Infect Dis 2002;43(3);207-217.
20. Pérez-Trallero E, García-Rey C, Martín- Sánchez AM, Aguilar L, García-De Lomas J, Ruiz J, et al. Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofioxacin in Spain. Antimicrob Agents Chemother 2002;46(8):2665-2667.
21. Legg JM, Bint AJ. Will pneumococci put quinolones in their place? J Antimicrob Chemother 1999;44:425-427.
22. Saravolatz L, Manzor O, Check C, Pawlak J, Belian B. Antimicrobial activity of moxifioxacin, gatifioxacin and six fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 2001;47(6):875-877.
23. Ball AP, Tillotson GS. Lower respiratory tract infections therapy-the role of ciprofioxacin. J Int Med Res 1995;23:315-327.
24. Hutchinson J. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;347(1):66-67.